Research programme: anti-cancer ligand proteins - EnchiraAlternative Names: ACL™ proteins; Anti-cancer ligand proteins research programme - Enchira; Receptor tyrosine kinase inhibitors research programme - Enchira
Latest Information Update: 13 Feb 2003
At a glance
- Originator Enchira Biotechnology Corporation [CEASED]
- Mechanism of Action Epidermal growth factor receptor antagonists; Epidermal growth factor stimulants; Insulin-like growth factor I inhibitors; Protein tyrosine kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 13 Feb 2003 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 01 Jul 2002 Preclinical trials in Cancer in USA (unspecified route)